In a significant move to address one of the most challenging frontiers in modern oncology, Expert Review of Gastroenterology & Hepatology—a flagship journal under the Taylor & Francis imprint—has officially issued an open call for submissions for a specialized Article Collection dedicated to "Biliary Cancer Prevention and Treatment."
As biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder cancer, continue to present formidable clinical hurdles, this initiative aims to consolidate the latest global research. The goal is to bridge the gap between bench-side molecular discoveries and bedside clinical practice, providing a comprehensive repository of evidence-based strategies for multidisciplinary care teams.
Main Facts: The Scope of the Article Collection
The initiative seeks to curate a high-impact collection of peer-reviewed content that reflects the complexity of biliary malignancies. The journal is inviting contributions from a diverse spectrum of specialists, including medical oncologists, hepatobiliary surgeons, gastroenterologists, and translational researchers.
The collection is designed to be inclusive of various formats, welcoming:
- Original Research: Data-driven studies that push the boundaries of current understanding.
- Review Articles: Syntheses of existing literature that provide clarity on rapidly evolving protocols.
- Drug Profiles: In-depth examinations of emerging pharmacotherapies.
- Editorials: Short-form, high-impact perspectives on the future of the field.
The primary thematic focus will be the diagnostic and therapeutic landscape of cholangiocarcinoma and gallbladder cancer. Specifically, the journal is looking for manuscripts that address the shift toward precision medicine, such as the use of molecular profiling to guide systemic therapy and the application of novel surgical techniques that improve patient quality of life.
Chronology: A Field in Rapid Transition
The call for papers arrives at a critical juncture in the history of hepatobiliary oncology. To understand the significance of this collection, one must examine the timeline of progress in the field over the last decade.
2015–2018: The Era of Recognition
For years, biliary cancers were classified as "orphan" or "neglected" diseases. During this period, the medical community began to recognize that these malignancies were not a single entity but a diverse group of tumors with distinct molecular signatures. Clinical trials began to focus more heavily on genomic sequencing, leading to the identification of actionable mutations such as IDH1 and FGFR2 fusions.
2019–2022: The Paradigm Shift
This period marked the approval of targeted therapies and immune checkpoint inhibitors for BTC. With the landmark results of trials like TOPAZ-1, which demonstrated the survival benefit of adding immunotherapy to standard chemotherapy, the standard of care shifted. Surgeons and oncologists began working more closely in multidisciplinary tumor boards, realizing that systemic therapy and surgical resection were no longer siloed approaches but interconnected strategies.
2023–Present: The Push for Early Detection
The current focus, which this Taylor & Francis collection intends to highlight, is on early detection. Because biliary cancers are often diagnosed at late stages when curative surgery is impossible, the research community is currently pivoting toward liquid biopsies, circulating tumor DNA (ctDNA) analysis, and advanced imaging biomarkers. This new collection serves as a marker for this transition, moving from "managing the late-stage disease" to "detecting and preventing at the earliest possible window."
Supporting Data: The Clinical Necessity
The urgency of this call to action is underscored by current epidemiological and clinical data. Biliary tract cancers remain among the most aggressive malignancies of the gastrointestinal tract.
The Diagnostic Challenge
Data indicates that a significant percentage of patients present with locally advanced or metastatic disease at the time of diagnosis. Unlike colorectal or breast cancer, there are currently no standard, widespread screening protocols for the general population. The Expert Review of Gastroenterology & Hepatology collection seeks to address this by focusing on:
- Molecular Profiling: Up to 40% of patients with intrahepatic cholangiocarcinoma may harbor actionable genomic alterations. Yet, consistent testing remains a challenge in many healthcare systems.
- Systemic Therapy Outcomes: While the introduction of combination immunotherapy has extended median overall survival, the absolute gains remain modest compared to other solid tumors. The medical community is in dire need of data on resistance mechanisms.
Surgical Innovation
Surgical resection remains the only potentially curative treatment. However, the complexity of the biliary anatomy makes these procedures high-risk. Recent studies suggest that the implementation of robotic-assisted surgery and better perioperative management have lowered morbidity rates. This collection aims to capture these technical refinements to help standardize care across global health centers.
Official Perspectives: The Editorial Vision
The commissioning process for this collection is being overseen by Olivia Clovis-Corbett, whose role as Commissioning Editor is to facilitate the inclusion of high-quality, actionable content.
In discussions regarding the vision for this collection, it is clear that the focus is on "translational impact." The editorial board of Expert Review of Gastroenterology & Hepatology has expressed that this is not merely an academic exercise. Rather, it is a response to the "clinician’s dilemma"—the constant struggle to apply rapidly emerging data to the individual patient sitting in the exam room.
"Our objective is to provide a roadmap for the future of patient care," says the editorial team. By inviting experts to submit work that ranges from molecular diagnostics to palliative care strategies, the journal intends to create a resource that is as relevant to the academic researcher as it is to the frontline clinician.
Implications: The Future of Biliary Cancer Care
The implications of this initiative extend far beyond the pages of a journal. By aggregating research on biliary cancer, Taylor & Francis is contributing to several systemic improvements in oncology:
1. Standardization of Care
One of the greatest challenges in hepatobiliary oncology is the disparity in care between high-volume, academic centers and community-based hospitals. By publishing evidence-based reviews and innovative protocols, the journal provides a standard reference point that can help elevate the quality of treatment for patients regardless of their geographic location.
2. Acceleration of Precision Medicine
The focus on biomarkers and molecular profiling is likely to catalyze further interest in companion diagnostics. If the research submitted to this collection demonstrates the efficacy of specific targeted therapies in diverse patient populations, it may influence future clinical guidelines, potentially leading to more rapid approval and adoption of these treatments by regulatory bodies like the FDA and EMA.
3. A Call to Multidisciplinary Collaboration
The explicit request for input from surgeons, oncologists, and gastroenterologists reinforces the necessity of the "multidisciplinary team" (MDT) model. As biliary cancers become more complex to treat, the days of the lone specialist making treatment decisions are over. This collection serves as a virtual MDT meeting, encouraging professionals from different sub-specialties to speak the same language and align their treatment goals.
4. Improving Patient Quality of Life
Ultimately, the goal of this research is patient outcomes. The emphasis on "management and care" suggests that the journal is interested not just in survival metrics, but in the quality of the life experienced by patients. Articles addressing nutritional support, pain management, and the psychological impact of aggressive malignancy will be vital components of this comprehensive collection.
How to Contribute: A Pathway to Impact
For researchers and clinicians who have been working in the trenches of biliary cancer, this is a strategic opportunity to contribute to a seminal body of work. The invitation is open, and the process is streamlined to ensure that timely research reaches the clinical audience as quickly as possible.
Authors interested in participating are encouraged to contact Olivia Clovis-Corbett to discuss their research ideas. Whether you are conducting a clinical trial on a novel systemic therapy, analyzing the surgical outcomes of a new technique, or writing an editorial on the future of biliary oncology, your work is a critical piece of the puzzle.
Submission Guidelines and Inquiries:
- Target Journal: Expert Review of Gastroenterology & Hepatology
- Focus Areas: Biliary cancer prevention, diagnosis, molecular profiling, surgical innovation, and systemic therapy.
- Contact: For submission inquiries or to learn more, reach out to Commissioning Editor Olivia Clovis-Corbett.
- Further Information: Visit the official Taylor & Francis portal to review the full scope and submission criteria.
In conclusion, the fight against biliary cancer is reaching a critical inflection point. As our understanding of the tumor microenvironment deepens and our surgical capabilities advance, the need for centralized, expert-reviewed knowledge has never been greater. By fostering this dialogue, Expert Review of Gastroenterology & Hepatology is doing more than just publishing a collection; they are actively shaping the future of a field that has for too long been left in the shadows of oncology. For the medical community, the message is clear: the data you have today could be the life-saving treatment of tomorrow.
About the Author
